vanta fda supply chain
5 Vanta Gaps Sabotaging Longevity Science Growth
Vanta’s gaps - weak supply-chain traceability, incomplete potency checks, automatic compliance marking, payment-processing drag, and logistics automation flaws - slow peptide development and erode data quality. Startups that ignore these blind spots see longer time-to-launch, higher costs, and shaky trial results. Recent audits show a 2-3 week average delay